Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas

Nirmal Verma, Gopal Viswanathan Velmurugan, Edric Winford, Han Coburn, Deepak Kotiya, Noah Leibold, Laura Radulescu, Sanda Despa, Kuey C. Chen, Linda J. Van Eldik, Peter T. Nelson, Donna M. Wilcock, Gregory A. Jicha, Ann M. Stowe, Larry B. Goldstein, David K. Powel, Jeffrey H. Walton, Manuel F. Navedo, Matthew A. Nystoriak, Andrew J. MurrayGeert Jan Biessels, Claire Troakes, Henrik Zetterberg, John Hardy, Tammaryn Lashley, Florin Despa

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Impairment of vascular pathways of cerebral β-amyloid (Aβ) elimination contributes to Alzheimer disease (AD). Vascular damage is commonly associated with diabetes. Here we show in human tissues and AD-model rats that bloodborne islet amyloid polypeptide (amylin) secreted from the pancreas perturbs cerebral Aβ clearance. Blood amylin concentrations are higher in AD than in cognitively unaffected persons. Amyloid-forming amylin accumulates in circulating monocytes and co-deposits with Aβ within the brain microvasculature, possibly involving inflammation. In rats, pancreatic expression of amyloid-forming human amylin indeed induces cerebrovascular inflammation and amylin-Aβ co-deposits. LRP1-mediated Aβ transport across the blood-brain barrier and Aβ clearance through interstitial fluid drainage along vascular walls are impaired, as indicated by Aβ deposition in perivascular spaces. At the molecular level, cerebrovascular amylin deposits alter immune and hypoxia-related brain gene expression. These converging data from humans and laboratory animals suggest that altering bloodborne amylin could potentially reduce cerebrovascular amylin deposits and Aβ pathology.

Original languageEnglish
Article number2
JournalCommunications Biology
Volume6
Issue number1
DOIs
StatePublished - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

Funding

Funding in part by: University of Kentucky Research Alliance to Reduce Diabetes-Associated Microvascular Dysfunction (ADAM) and National Institutes of Health R01 NS116058, R01 AG057290, R01 AG053999, R01 HL 149127 and P30 AG028383, and Alzheimer’s Association VMF-15-363458. UK Dementia Research Institute which receives its funding from DRI Ltd, funded by: the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK; Medical Research Council (award number MR/N026004/1); Wellcome Trust Hardy (award number 202903/Z/16/Z); Dolby Family Fund; National Institute for Health Research University College London Hospitals Biomedical Research Center; BRCNIHR Biomedical Research Center at University College London Hospitals NHS Foundation Trust and University College London. H.L. was supported by an American Heart Association fellowship (18PRE33990154). T.L. is supported by an Alzheimer’s Research UK Senior Fellowship. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003).

FundersFunder number
AD Strategic Fund-21-831376-C, -21-831377-C
European Union Joint Program – Neurodegenerative Disease ResearchJPND2021-00694
National Institute for Health Research University College London Hospitals Biomedical Research Center
Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden2019-0228
Swedish State Support for Clinical Research-71320
Alltech-University of Kentucky Nutrition Research Alliance
Wellcome Trust Hardy202903/Z/16/Z
National Institutes of Health (NIH)R01 NS116058, P30 AG028383, R01 AG057290, R01 AG053999, R01 HL 149127
National Institutes of Health (NIH)
Alzheimer's AssociationVMF-15-363458
Alzheimer's Association
American the American Heart Association18PRE33990154
American the American Heart Association
Alzheimer's Drug Discovery Foundation201809-2016862
Alzheimer's Drug Discovery Foundation
Familjen Erling-Perssons Stiftelse
Horizon 2020 Framework Programme
H2020 Marie Skłodowska-Curie Actions860197
H2020 Marie Skłodowska-Curie Actions
Dolby Family Ventures
Medical Research CouncilMR/N026004/1
Medical Research Council
Alzheimer's Society
University of London, King's College London, UK
H2020 European Research Council101053962, 681712
H2020 European Research Council
Alzheimer’s Research United Kingdom
Vetenskapsrådet2018-02532
Vetenskapsrådet
University College London Hospitals NHS Foundation Trust
UK Dementia Research InstituteUKDRI-1003
UK Dementia Research Institute
Olav Thon Stiftelsen

    ASJC Scopus subject areas

    • Medicine (miscellaneous)
    • General Biochemistry, Genetics and Molecular Biology
    • General Agricultural and Biological Sciences

    Fingerprint

    Dive into the research topics of 'Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas'. Together they form a unique fingerprint.

    Cite this